Workflow
辰欣药业(603367) - 2022 Q1 - 季度财报
CISENCISEN(SH:603367)2022-04-26 16:00

Financial Performance - The company's operating revenue for Q1 2022 was ¥869,770,720.65, a decrease of 0.45% compared to the same period last year[6] - The net profit attributable to shareholders was ¥96,747,943.51, down 10.99% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥90,935,465.75, a decline of 12.07% compared to the previous year[6] - Basic and diluted earnings per share were both ¥0.21, reflecting a decrease of 12.50%[9] - Total operating revenue for Q1 2022 was CNY 869,770,720.65, a slight decrease of 0.11% compared to CNY 873,706,286.17 in Q1 2021[30] - Net profit for Q1 2022 was CNY 96,618,150.94, a decrease of 11.1% compared to CNY 108,638,309.59 in Q1 2021[32] - Earnings per share for Q1 2022 was CNY 0.21, down from CNY 0.24 in Q1 2021[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,311,113,641.66, a decrease of 0.83% from the end of the previous year[9] - The total assets of the company were CNY 6.31 billion, slightly down from CNY 6.36 billion, indicating a decrease of approximately 0.8%[26] - Current liabilities totaled CNY 1.07 billion, a decrease from CNY 1.22 billion, representing a decline of about 11.9%[26] - The total liabilities decreased to CNY 1,158,224,628.91 from CNY 1,308,143,576.19 year-over-year[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,903[16] - The largest shareholder, Chenxin Technology Group Co., Ltd., held 36.55% of the shares, with 89,709,609 shares pledged[16] - Total equity attributable to shareholders increased to CNY 5,152,516,195.37 from CNY 5,054,821,024.66 year-over-year[30] Cash Flow - The cash flow from operating activities showed a net increase of 277.85% due to reduced cash payments related to operating activities[15] - Cash flow from financing activities showed a net outflow of -1,148,694.45, compared to -182,776,935.90 in the previous year[40] - The net cash flow from operating activities was 48,644,592.93, a significant improvement compared to the previous year's negative cash flow of -27,351,739.44[38] - The company received 6,613,149.02 in cash related to operating activities, a decrease from 36,077,528.47 in the previous year[38] Current Assets and Inventory - As of March 31, 2022, total current assets amounted to approximately CNY 4.02 billion, a decrease from CNY 4.14 billion as of December 31, 2021, reflecting a decline of about 3.0%[23] - The company's cash and cash equivalents were reported at CNY 794.63 million, down from CNY 938.98 million, indicating a decrease of approximately 15.3% year-over-year[23] - Accounts receivable increased to CNY 615.89 million from CNY 508.21 million, representing a growth of about 21.2%[23] - Inventory levels rose to CNY 605.91 million, compared to CNY 594.65 million, marking an increase of approximately 1.9%[23] Research and Development - Research and development expenses for Q1 2022 were CNY 64,917,148.86, compared to CNY 69,613,602.09 in Q1 2021, reflecting a decrease of 6.1%[32] Financial Expenses - The company reported a financial expense of CNY -7,011,265.62 in Q1 2022, compared to CNY 519,867.38 in Q1 2021, indicating a significant improvement[32] Other Financial Metrics - Cash paid for employee compensation increased to 87,361,363.19 from 78,757,933.00 year-over-year[38] - The cash paid for taxes was 109,746,643.19, slightly down from 113,033,889.22 in the previous year[38] - Cash received from investment income was 7,000,527.80, a decrease from 19,832,795.21 year-over-year[38] - The company experienced a negative impact of -159,584.76 from foreign exchange fluctuations on cash and cash equivalents[40]